Preclinical characterization of LY3962673, an orally bioavailable, highly potent, and selective KRAS G12D inhibitor

被引：3
|
作者：
Iyer, Chandrasekar
Li, Binghui
Stewart, Trent R.
Wang, Tao
Capen, Andrew
Cavitt, Rachel
Anderson, Bryan D.
Bocchinfuso, Wayne
Zhao, Gaiying
Rodriguez, Michael J.
Carballares, Santiago
Cooke, Andrew
Bondi, Robert
Burns, Lee
Kelamangalath, Lakshmi
Wallace, Ross
Kolakowski, Gabrielle
Henry, James R.
Si, Chong
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2023年 / 22卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-23-B115
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B115
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Non-clinical identification and characterization of KRAS G12D inhibitors
    Brooun, A.
    Bae, J. H.
    Chen, H.
    Li, P.
    Lin, B.
    Fagan, P.
    Irimia, A.
    Nevarez, R.
    Zhang, J.
    Chen, P.
    Olaharski, D.
    Chiang, G.
    Vernier, J. M.
    Shoemaker, R.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S19 - S19
  • [22] GFH375 (VS-7375): An oral, selective KRAS G12D (ON/ OFF) inhibitor with potent anti-tumor efficacy
    Yan, Feng
    Jiang, Tao
    Liang, Tao
    Cai, Lijian
    Zhang, Leitao
    Xu, Xiaoming
    Zhao, Yanhui
    Lan, Xiaoling
    Zhang, Xiaohui
    Liu, Meng
    Liu, Qiang
    Gao, Jinting
    Xie, Fubo
    Gao, Xueyan
    Wang, Li
    Zhang, Jingyang
    Ren, Hongcan
    Liu, Dong
    Le, Siyuan
    Tang, Lili
    Coma, Silvia
    Cheng, Yaofeng
    Sanburn, Nathan
    Pachter, Jonathan A.
    Zhou, Fusheng
    Lan, Jiong
    Lu, Qiang
    CANCER RESEARCH, 2024, 84 (06)
  • [23] KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
    Mao, Zhongwei
    Xiao, Hongying
    Shen, Panpan
    Yang, Yu
    Xue, Jing
    Yang, Yunyun
    Shang, Yanguo
    Zhang, Lilan
    Li, Xin
    Zhang, Yuying
    Du, Yanan
    Chen, Chun-Chi
    Guo, Rey-Ting
    Zhang, Yonghui
    CELL DISCOVERY, 2022, 8 (01)
  • [24] HBW-012-D and HBW-012-E are novel, potent, selective, safe, and bioavailable KRAS G12D inhibitors with superior anti-tumor efficacy in mice
    Lee, Ning
    Li, Yingfu
    Liu, Guanfeng
    Li, Jiang
    Ren, Junfeng
    CANCER RESEARCH, 2024, 84 (06)
  • [25] KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
    Zhongwei Mao
    Hongying Xiao
    Panpan Shen
    Yu Yang
    Jing Xue
    Yunyun Yang
    Yanguo Shang
    Lilan Zhang
    Xin Li
    Yuying Zhang
    Yanan Du
    Chun-Chi Chen
    Rey-Ting Guo
    Yonghui Zhang
    Cell Discovery, 8
  • [26] Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study
    Kuboki, Yasutoshi
    Murciano-Goroff, Yonina R.
    Yaeger, Rona
    Cassier, Philippe Alexandre
    Heist, Rebecca Suk
    Fujiwara, Yutaka
    Deming, Dustin A.
    Ammakkanavar, Natraj
    Patnaik, Amita
    Shimizu, Toshio
    Call, Justin
    Han, Sae-Won
    Fink, Aaron Alan
    Chen, Aaron
    Willard, Melinda D.
    Balar, Arjun Vasant
    Koyama, Takafumi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 94 - 94
  • [27] Characterization of the properties of a selective, orally bioavailable autotaxin inhibitor in preclinical models of advanced stages of liver fibrosis
    Baader, Manuel
    Bretschneider, Tom
    Broermann, Andre
    Rippmann, Joerg F.
    Stierstorfer, Birgit
    Kuttruff, Christian A.
    Mark, Michael
    BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (04) : 693 - 707
  • [28] A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors
    Murciano-Goroff, Yonina R.
    Heist, Rebecca S.
    Kuboki, Yasutoshi
    Koyama, Takafumi
    Ammakkanavar, Natraj Reddy
    Hollebecque, Antoine
    Patnaik, Amita
    Shimizu, Toshio
    Spira, Alexander I.
    Nagasaka, Misako
    Han, Ji-Youn
    Iams, Wade Thomas
    Deming, Dustin
    Call, Justin
    Cassier, Philippe
    Han, Sae-Won
    Chu, Quincy Siu-Chung
    Cosman, Rasha
    Durm, Gregory
    Burns, Timothy
    Willard, Melinda D.
    Liu, Shiyao
    Callies, Sophie
    Balar, Arjun V.
    Sabari, Joshua K.
    CANCER RESEARCH, 2023, 83 (08)
  • [29] Discovery and Characterization of ZL-2201, a Potent, Highly Selective, and Orally Bioavailable Small-molecule DNA-PK Inhibitor
    Lal, Shruti
    Bhola, Neil E.
    Sun, Bee-Chun
    Chen, Yuping
    Huang, Tom
    Morton, Vivian
    Chen, Kevin X.
    Xia, Shanghua
    Zhang, Haoyu
    Parikh, Nehal S.
    Ye, Qiuping
    Veiby, O. Petter
    Bellovin, David I.
    Ji, Yuhua
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (09): : 1731 - 1742
  • [30] A first-in-human phase I study of a novel KRAS G12D inhibitor HRS-4642 in patients with advanced solid tumors harboring KRAS G12D mutation
    Zhou, C.
    Li, W.
    Song, Z.
    Zhang, Y.
    Zhang, Y.
    Huang, D.
    Yang, Z.
    Zhou, M.
    Mao, R.
    Huang, C.
    Li, X.
    Wang, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1273 - S1273
12345